Creo Medical kicks off landmark lung tumour study with MicroBlate Flex device
Published: 02:30 10 Jul 2025 EDT
Creo Medical Group PLC (AIM:CREO), the AIM-listed medical device company, has treated its first patient in a new clinical study testing its MicroBlate Flex device for lung tumour treatment.
The evaluation, running at Amsterdam University Medical Centre and London’s Royal Brompton Hospital, is designed to assess how well the MicroBlate Flex performs when used to ablate – destroy, in other words – lung tumours before surgical removal.
By analysing the tumour after surgery, doctors can compare the actual results to pre- and post-treatment scans, giving a clear picture of the device’s effectiveness.
This latest study adds to Creo’s ongoing clinical work, including another post-market trial focused on patient safety and long-term follow-up, as well as a partnership with Intuitive.
The latter involves robotically guided tumour ablation using MicroBlate Flex combined with Intuitive’s Ion system, aiming to build a strong clinical case before the device becomes widely available.
"Our collaboration with Intuitive further strengthens our emerging position at the forefront of minimally invasive lung cancer treatment and highlights the broad potential of MicroBlate Flex as we move toward commercialisation," said CEO Craig Gulliford.
The technology is designed to treat soft tissue tumours and nodules, with lung cancer being a key focus.
Lung cancer remains one of the most common cancers worldwide, and current treatments such as chemotherapy, radiation, and surgery can be tough on patients.
Creo’s device aims to offer a less invasive alternative, potentially improving outcomes and recovery.
